Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma - The DD protocol

dc.contributorUniversidade Estadual Paulista (UNESP)
dc.creatorDulley, Frederico Luiz
dc.creatorSaboya, Rosaura
dc.creatorde Moraes Hungria, Vãnia Tietsche
dc.creatorBueno, Nadjanara Dorna
dc.creatorde Mello, Fernando Gomes
dc.creatorFrota, Maria Tereza
dc.creatorChiattone, Carlos Sergio
dc.creatorBarros, José Carlos
dc.creatorMori, Nair Sumie
dc.creatorSturaro, Daniel
dc.creatorde Almeida Macedo, Maria Cristina Martins
dc.creatorda Silva, Roberto Luiz
dc.creatorde Melo, Leila Maria Magalhães Pessoa
dc.creatorSouza, Cármino Antonio
dc.date2014-05-27T11:21:40Z
dc.date2016-10-25T18:21:17Z
dc.date2014-05-27T11:21:40Z
dc.date2016-10-25T18:21:17Z
dc.date2005-11-01
dc.date.accessioned2017-04-06T01:15:16Z
dc.date.available2017-04-06T01:15:16Z
dc.identifierSao Paulo Medical Journal, v. 123, n. 6, p. 266-270, 2005.
dc.identifier1516-3180
dc.identifierhttp://hdl.handle.net/11449/68477
dc.identifierhttp://acervodigital.unesp.br/handle/11449/68477
dc.identifier10.1590/S1516-31802005000600003
dc.identifierS1516-31802005000600003
dc.identifier2-s2.0-33750046937.pdf
dc.identifier2-s2.0-33750046937
dc.identifierhttp://dx.doi.org/10.1590/S1516-31802005000600003
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/889812
dc.descriptionContext and Objective: Lipasomial daunorubicin has been used to treat hematological malignancies, including multiple myelomo (MM). The goal was to evaluate efficacy, side-effects and toxicity of liposomal daunorubicin and dexamethasone (DD Protocol). Design and Setting: Prospective study of Sírio-Libonês, São Camilo, Brasil and Alemão Oswaldo Cruz hospitals. Methods: Twenty consecutive patients with active MM received four cycles of liposomal daunorubicin intravenously for two hours (25-30 mg/m 2/day) on three consecutive days per month, with oral dexamethasone, (10 mg every six hours) on four consecutive days three times a month. Results: The male/female ratio was 1:1 and median age 60. Nine patients were stage IIA, ten IIIA and one IIIB. The median from diagnosis to starting DD was 13 months. All patients received four cycles, except one. Fifteen had already received chemotherapy before DD. Responses of > 50% reduction in serum monoclonal paraprotein were observed in six patients after first cycle (30%), six after second (30%) and four after third (20%), while four (20%) did not obtain this. Initially, 17 patients (85%) had anemia: 12 (70%) achieved correction. Progressive disease was observed in three patients (15%), while one had minimal response, four (20%) partial and 12 (60%) complete. Hemotologlical toxicity was acceptable: three patients (15%) had neutrophils < 1,000/mm 3; none had thrombocyfopenia. Gastrointestinal toxicity was mild: nausea (10%), anorexio (15%) and no vomiting. Conclusions: This treatment has mild toxicity and good response rate. It may therefore be feasible before autologous bone marraw transplantation.
dc.languageeng
dc.relationSão Paulo Medical Journal
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDaunorubicin
dc.subjectDexamethasone
dc.subjectDrug theraphy
dc.subjectDrug toxicity
dc.subjectMultiple myeloma
dc.subjectbleomycin
dc.subjectcyclophosphamide
dc.subjectdaunorubicin
dc.subjectdexamethasone
dc.subjectdoxorubicin
dc.subjectliposome
dc.subjectmelphalan
dc.subjectparaprotein
dc.subjectprednisone
dc.subjectvincristine
dc.subjectadult
dc.subjectaged
dc.subjectalopecia
dc.subjectanemia
dc.subjectanorexia
dc.subjectasthenia
dc.subjectautologous bone marrow transplantation
dc.subjectBrazil
dc.subjectcancer combination chemotherapy
dc.subjectcancer growth
dc.subjectcancer staging
dc.subjectcardiotoxicity
dc.subjectclinical article
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdose response
dc.subjectdrug efficacy
dc.subjectdrug fatality
dc.subjectdrug response
dc.subjectdrug safety
dc.subjectfeasibility study
dc.subjectfemale
dc.subjectgastrointestinal symptom
dc.subjecthematologic malignancy
dc.subjecthuman
dc.subjectmale
dc.subjectmultiple myeloma
dc.subjectnausea
dc.subjectneutropenia
dc.subjectpneumonia
dc.subjectprospective study
dc.subjectprotein blood level
dc.subjectthrombocytopenia
dc.subjecturinary tract infection
dc.subjectvomiting
dc.subjectAdult
dc.subjectAged
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectDrug Administration Schedule
dc.subjectFemale
dc.subjectHumans
dc.subjectLiposomes
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMultiple Myeloma
dc.subjectParaproteins
dc.subjectProspective Studies
dc.subjectTreatment Outcome
dc.titleLiposomal daunorubicin and dexamethasone as a treatment for multiple myeloma - The DD protocol
dc.typeOtro


Este ítem pertenece a la siguiente institución